Lyell Immunopharma, Inc.
LYEL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.00 | 0.01 | -0.00 |
| FCF Yield | -9.65% | -26.48% | -34.63% | -27.72% |
| EV / EBITDA | -5.99 | -2.05 | -1.77 | -2.15 |
| Quality | ||||
| ROIC | -9.91% | -13.20% | -14.46% | -45.20% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.74 | 0.81 | 1.05 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -90.54% | -89.26% | -90.83% | -91.04% |
| Free Cash Flow Growth | 17.29% | 37.03% | -16.28% | -34.71% |
| Safety | ||||
| Net Debt / EBITDA | 2.19 | 1.03 | 1.17 | 0.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |